治疗小儿支原体肺炎4种不同方案的成本及效果分析

The Cost-effective analysis of four methods in treating childish mycoplasmal pneumonia

目的评价4种不同方案治疗小儿支原体肺炎的药物经济学效果。方法运用药物经济学成本-效果分析法,对阿奇霉素-阿奇霉素序贯疗法组(A组)、(阿奇霉素+氨溴索)-阿奇霉素序贯疗法组(B组)、红霉素-阿奇霉素序贯疗法组(C组)和(红霉素+氨溴索)-阿奇霉素序贯疗法组(D组)4种治疗方案进行回顾性分析评价。结果4组治愈率分别为78.95%、87.80%、82.05%、88.89%(χ2=5.27,P>0.05);成本分别为(1268.6±126.5)、(1185.3±114.2)、(1124.2±105.3)、(1062.4±96.6)元(F=2.78,P<0.05);成本-效果比分别为16.07±1.60、13.50±1.30、13.70±1.28和11.95±1.09(F=3.98,P<0.01)。结论D组为最佳治疗方案。

Objective To evaluate the pharmaceutical economics effect of four methods in treating infection on childish mycoplasmal pneumonia.Methods Evaluate the four treating projects in retrospect by cost-effective analysis,including azithromycin-azithromycin sequential therapy group(A),(azithromycin-allied ambroxol)-azithromycin sequential therapy group(B),erythromycin-azithromycin sequential therapy group(C)and(erythromycin-allied ambroxol)-azithromycin sequential therapy group(D).Results The recovery rates of these four groups were 78.95%、 87.80%、 82.05%、 88.89%(χ2=5.27,P>0.05)respectively;the costs of the four groups were(1268.6±126.5)、(1185.3±114.2)、(1124.2±105.3)、(1062.4±96.6)Yuan(F=2.78,P<0.05);the cost-effectiveness scores were 16.07±1.60,13.50±1.30,13.70±1.28 and 11.95±1.09(F=3.98,P<0.01).Conclusion The project of Group D was the best one for treating infection on childish mycoplasmal pneumonia.